• 1
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE for the Fracture Intervention Trial Research Group 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:15351541.
  • 2
    Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:8391.
  • 3
    Ettinger B, Black DM, Mitalk BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637645.
  • 4
    Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231236.
  • 5
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D for the Fracture Intervention Trial Research Group 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:12461254.
  • 6
    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:15861592.
  • 7
    Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281289.
  • 8
    Sarkar S, Mitlak BH, Wong M, Stock J, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:110.
  • 9
    Li Z, Meredith MP, Hoseyni MS 2001 A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:31753188.
  • 10
    Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, Rosen C 2002 Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endrocinol Metab Clin North Am 31:659679.
  • 11
    Delmas PD 2000 How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 27:13.
  • 12
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix A for the Fracture Intervention Trial Research Group 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:20772082.
  • 13
    Black D, Thompson DE, Bauer D, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 85:41184124.
  • 14
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD for the Vertebral Efficacy with Risedronate (VERT) Study Group 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:13441352.
  • 15
    Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D for the PROOF Study Group 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 109:267276.
  • 16
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriquez-Portales J, Downs RW, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:14371443.
  • 17
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH 1990 Effect of intermittent cyclical etidronate therapy on bone mass and fracture risk in women with postmenopausal osteoporosis. N Engl J Med 322:12651271.
  • 18
    Bone HG, Downs RW, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ 1997 Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 82:265274.
  • 19
    Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH 1997 Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med 103:468476.
  • 20
    Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL 1992 Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:19.
  • 21
    Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL 1998 Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Miner Res 13:17471754.
  • 22
    Overgaard K, Hansen MA, Jensen SB, Christiansen C 1992 Effect of salcalcitonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ 305:556561.
  • 23
    Genant HK, Chesnut CH, Eisman JA, Harris ST, McClung MH, Prince KL, Recker RR, Seeman E, Siris ES, Stutridge WC, Wasnidn RD, Tou CKP, Heshman HM. 1998 Chronic intermittent cyclical administration of tiludronate in postmenopausal osteoporosis: Report of two multicenter studies in 2316 patients. Bone 23(Suppl 5):S175.
  • 24
    Huque ME 1988 Experience with meta-analysis in NDA submissions. Proc Biopharm Sec Am Stat Assoc 2:2833.
  • 25
    Li Z, Meredith MP 2003 Exploring the relationship between surrogates and clinical outcomes: Analysis of individual patient data vs. meta-regression on group-level summary statistics. J Biopharm Stat 13:773788.
  • 26
    Shih J, Bauer DC, Orloff J, Capizzi T, Thompson D, Oppenheimer L, Ross PD 2002 Proportion of fracture risk reduction explained by BMD changes using Freedman analysis depends on choice of predictors. Osteoporos Int 13(Suppl 3):S38.
  • 27
    Freedman LS, Grauband BI, Schatzkin A 1992 Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167178.
  • 28
    Bjarnasson NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922930.
  • 29
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction of fracture risk with risedronate. J Bone Miner Res 18:10511056.
  • 30
    Bauer DC, Black DM, Garnero P, Hochberg M, Oh SM, Schneider DL, Thompson D, Orloff J, Ewing S, Delmas PD 2002 Reduction in bone turnover predicts hip non-spine and vertebral fracture in alendronate treated women: The fracture intervention trial. Osteoporos Int 13:521.
  • 31
    Delmas PD 2002 Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 30:1417.
  • 32
    Riggs BL, Melton LJ 2002 Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:1114.
  • 33
    Watts NB 2002 Bone quality: Getting closer to a definition. J Bone Miner Res 17:11481150.
  • 34
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687694.